Phase 2 trial results A phase 2, double-blind, randomised, placebo-controlled trial involving 338 adults with obesity or overweight revealed the potent weight-loss capabilities of retatrutide
Mitochondrial complex I as a pathologic and therapeutic target for Parkinsons disease
With over half the global population projected to have overweight or obesity by 2035, and excess weight contributing to millions of cardiovascular deaths annually, semaglutide offers a new approach to addressing one of medicine's most pressing challenges
Even modest doses of GLP-1 medications can reduce inflammation, especially when combined with other anti-inflammatory interventions like improved diet, regular movement, stress reduction, and better sleep
Please bring a list of your current medications and any recent lab results